First-in-human study of AT13148, a dual ROCK-AKT inhibitor in patients with solid tumors

PURPOSE: AT13148 is an oral AGC kinase inhibitor, which potently inhibits ROCK and AKT kinases. In preclinical models, AT13148 has been shown to have anti-metastatic and anti-proliferative activity. EXPERIMENTAL DESIGN: The trial followed a rolling six design during dose escalation. An intra-patient...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Autores principales: McLeod, Robert, Kumar, Rajiv, Papadatos-Pastos, Dionysis, Mateo, Joaquin, Brown, Jessica S, Garces, Alvaro H Ingles, Ruddle, Ruth, Decordova, Shaun, Jueliger, Simone, Ferraldeschi, Roberta, Maiques, Oscar, Sanz-Moreno, Victoria, Jones, Paul, Traub, Stephanie, Halbert, Gavin, Mellor, Sarah, Swales, Karen E, Raynaud, Florence I, Garrett, Michelle D, Banerji, Udai
Formato: Artigo
Lenguaje:Inglês
Publicado: 2020
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7611345/
https://ncbi.nlm.nih.gov/pubmed/32616501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0700
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares